Longevity drugs after 40: what the human trials measured

Text written with the help of AI.

Trials of metformin, bimagrumab and rapamycin have measured different kinds of benefit. Reading those results closely helps answer a practical question: does the evidence support the reason you might take one of these drugs after 40?

Metformin: diabetes prevention in people at high risk

The Diabetes Prevention Program enrolled 3,234 adults with elevated glucose levels. Over approximately three years, diabetes incidence was 31% lower in the metformin group and 58% lower in the intensive lifestyle group than in the placebo group. These were relative reductions in diabetes diagnoses. The lifestyle programme included structured support for diet, activity and weight loss. Diabetes Prevention Program Research Group, 2002; NIDDK study description.

Avoiding diabetes is a meaningful outcome for someone at high risk. It does not establish that metformin extends life. In a follow-up analysis covering a median of 21 years, neither original intervention was associated with a reduction in all-cause mortality. After the initial trial, all groups were offered a modified lifestyle programme, and medication use changed over time. The follow-up cannot be read as a comparison between people who remained on separate treatments throughout those years. Nor did the study test metformin as a longevity drug in metabolically healthy adults. Lee and colleagues, 2021.

If you take metformin for a medical reason, its value belongs in a discussion about that condition with your prescriber. Uncertainty about lifespan is not, by itself, a reason to stop treatment.

Bimagrumab: more lean mass, without a demonstrated gain in function

Bimagrumab was investigated for sarcopenia, rather than tested as a general longevity treatment. Its trial is relevant because preserving muscle is often proposed as a way to preserve independence.

Researchers assigned 180 adults aged 70 or older with sarcopenia to bimagrumab or placebo. Both groups received nutritional support and home-based exercise. After 24 weeks, lean body mass had risen by approximately 7% in the drug group and 1% in the placebo group. The trial did not find a statistically significant advantage on its primary physical-performance measure; differences in walking speed and six-minute walking distance were also not statistically significant. Rooks and colleagues, 2020.

The measured change in body composition and the absence of a demonstrated functional advantage can both be true. This trial does not show that muscle mass is unimportant, or rule out a benefit in another population. It leaves unanswered whether increasing lean mass with this drug helps people remain mobile. Participants already had sarcopenia and were at least 70; the findings cannot be carried over directly to preventive use in healthy people decades younger.

Rapamycin: a mouse lifespan result and narrower human tests

Rapamycin extended lifespan in a study of genetically heterogeneous mice, including when treatment began late in their lives. That result gives researchers a reason to investigate the drug. Human studies must establish human outcomes separately. Harrison and colleagues, 2009.

In the 2025 PEARL trial, intermittent rapamycin was studied over 48 weeks. Among 114 participants who completed the study and were analysed, the primary outcome, visceral fat measured by a body-composition scan, did not improve significantly. Researchers reported some secondary findings in women, including changes in lean tissue mass and self-reported pain. Those findings do not establish slower ageing or longer survival. Adverse-event rates were similar across groups during the study, which cannot establish safety over many years. PEARL investigators, 2025.

The interpretation is further limited by the exclusion of participants who discontinued and by a separate assessment suggesting lower drug exposure from the compounded formulation used in the trial. Several authors were employees and shareholders of AgelessRx. These details matter when deciding how much weight to place on the findings.

A second trial, RAPA-EX-01, tested whether weekly rapamycin improved the benefits of a 13-week home exercise programme in 40 sedentary adults aged 65 to 85. Both groups improved on the primary measure, the number of chair stands completed in 30 seconds. Rapamycin did not enhance that gain in the main analysis. Additional prespecified analyses suggested smaller gains with rapamycin, while the main between-group difference was not statistically significant. The drug group had more adverse events in total, including one case of pneumonia considered possibly drug-related. This small, short trial cannot settle long-term effects, but it gives no support to assuming that adding rapamycin improves exercise gains. Stanfield and colleagues, 2026.

What the evidence supports

The question to ask of a proposed longevity drug is specific: which outcome improved, compared with what, and in whom? Metformin reduced diabetes incidence in people at high risk. Bimagrumab increased lean mass without a demonstrated advantage in the functional outcomes measured. The rapamycin trials discussed here have not established longer human life or a consistent improvement in physical function.

Tracking your own measurements or performance may describe what happens while you take a drug. It cannot show how you would have fared without it, particularly when exercise, diet or other care changes at the same time. For elective longevity use, waiting for trials that measure the benefit you seek is a defensible choice. Treatment for an existing condition calls for a separate decision with a clinician.

Sources